

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
In re PATENT APPLICATION OF

Darrell R. Anderson et al.

Group Art Unit: 1644

Application Serial No. 09/576,424

Examiner: P. Gambel

Filed: May 22, 2000

Title: IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND
THE HUMAN B7.1 AND B7.2 STIMULATORY ANTIGENS

* * * * *

ELECTION REPLY

Hon. Commissioner of Patents
Washington, D.C. 20231

RECEIVED

JUL 3 2002

TECH CENTER 1600/2900

Sir:

In response to the Office Action mailed on May 31, 2002, Applicants elect as the immunosuppressant species for purposes of examination CTLA-4-Ig or soluble CTLA-4.

This election is only for purposes of examination.

Also, it should be noted that in the previous election Applicants elected treatment of Crohn's disease with an anti-B7.1 (CD86) antibody according to the invention and merely present a dependent claim to provide for protocols wherein the elected antibody treatment is combined with another immunosuppressant. However, this is optional, and Applicants do not want the Examiner to limit his search to combination therapies as this is narrower than Applicants election which was intended to be generic to any treatment of Crohn's disease using an anti-B7.1 antibody according to the invention.

If the Examiner has any questions relating to this Election he is respectfully requested to contact the undersigned.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: Robin L. Teskin
Robin L. Teskin
Registration No. 35,030

1600 Tysons Boulevard
McLean, Virginia 22102
(703) 905-2000
(703) 905-2500 Facsimile
Date: July 1, 2002
Attorney Reference: 037003-0275681
/af

Inventor(s): Anderson et al.

Appl. No.: 09

576,424

Series Code ↑

Serial No. ↑

Filed: May 22, 2000

Hon. Commissioner of Patents

Washington, D.C. 20231

Sir:

REPLY/AMENDMENT/LETTER

Group Art Unit 1644

Examiner: P. Gambel

Atty. Dkt.

P 0275681

1995-30-0233CP2

M#

Client Ref

Appl. Title:

Identification of Unique Binding
Interactions Between Certain Antibodies
and the Human B7.1 and B7.2
Stimulatory Antigens

JUL 0 1 2002

JUL 3 2002

TELEPHONE CENTER 1600/2900

Date: July 1, 2002

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim

- A. ☒ NOT made
B. ☐ Withdrawn
C. ☐ made herewith
D. ☐ made previously

For B & C
See **Required
Separate Paper**
(Pat-256)

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	**minus	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	***minus	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)			add	+ \$280/\$140 =	+ \$0 104/204
5. Original due Date: June 30, 2002		<input type="checkbox"/> NONE			
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo) \$110/\$55 = (2 mos) \$400/\$200 = (3 mos) \$920/\$460 = (Usable only for ≤ 2mo.OA --- 4 mos) \$1,440/\$720= (Usable only for 30 day/1mo.OA --- 5 mos) \$1,960/\$980=	+ \$		115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract			- \$0		
8. Extension Fee Attached			+ \$0		
9. If Terminal Disclaimer attached, add Rule 20(d) official fee			+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c),			+ \$180	+ \$0	126
or if Rule 97(d) Request			+ \$180		126
11. After-Final Request Fee per rules 129(a) and 17(r)			+ \$740/370	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b).....			x \$740/370 ea	+ \$0	149/249
13. Request for Continued Examination (RCE)			+ \$740/370	+ \$0	1179/1279
14. Petition fee for				+ \$0	
15. TOTAL FEE ENCLOSED =				\$0	

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 037003 0275681

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.


This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Robin L. Teskin

Sig:



Reg. No. 35,030

1600 Tysons Boulevard

McLean, VA 22102

Tel: (703) 905-2000

Fax: (703) 905-2500

Tel: (703) 905-2200

Atty/Sec: RLT/af

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments